Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)

M. Herman Chui; Susanne K. Kjaer; Kirsten Frederiksen; Charlotte G. Hannibal; Tian Li Wang; Russell Vang; Ie Ming Shih

doi:10.18632/oncotarget.28001

Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)

M. Herman Chui
, Susanne K. Kjaer
, Kirsten Frederiksen
, Charlotte G. Hannibal
, Tian Li Wang
, Russell Vang
, Ie Ming Shih

Johns Hopkins University
Danish Cancer Society
University of Copenhagen

Research output: Contribution to journal › Comment/debate

Abstract

This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original language	English
Pages (from-to)	1323-1324
Number of pages	2
Journal	Oncotarget
Volume	12
Issue number	13
DOIs	https://doi.org/10.18632/oncotarget.28001
State	Published - 22 06 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021 Impact Journals LLC. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.18632/oncotarget.28001

Cite this

Chui, M. H., Kjaer, S. K., Frederiksen, K., Hannibal, C. G., Wang, T. L., Vang, R., & Shih, I. M. (2021). Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326). Oncotarget, 12(13), 1323-1324. https://doi.org/10.18632/oncotarget.28001

@article{3fb94dcacee2420d8146921eb66a58e3,

title = "Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)",

abstract = "This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.",

author = "Chui, \{M. Herman\} and Kjaer, \{Susanne K.\} and Kirsten Frederiksen and Hannibal, \{Charlotte G.\} and Wang, \{Tian Li\} and Russell Vang and Shih, \{Ie Ming\}",

year = "2021",

month = jun,

day = "22",

doi = "10.18632/oncotarget.28001",

language = "英语",

volume = "12",

pages = "1323--1324",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "13",

}

Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326). / Chui, M. Herman; Kjaer, Susanne K.; Frederiksen, Kirsten et al.
In: Oncotarget, Vol. 12, No. 13, 22.06.2021, p. 1323-1324.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Errayum

T2 - BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)

AU - Chui, M. Herman

AU - Kjaer, Susanne K.

AU - Frederiksen, Kirsten

AU - Hannibal, Charlotte G.

AU - Wang, Tian Li

AU - Vang, Russell

AU - Shih, Ie Ming

PY - 2021/6/22

Y1 - 2021/6/22

N2 - This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

AB - This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

UR - https://www.scopus.com/pages/publications/85108970371

U2 - 10.18632/oncotarget.28001

DO - 10.18632/oncotarget.28001

M3 - 评论/辩论

C2 - 34194631

AN - SCOPUS:85108970371

SN - 1949-2553

VL - 12

SP - 1323

EP - 1324

JO - Oncotarget

JF - Oncotarget

IS - 13

ER -

Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this